MX2019005756 DOMINIO DE UNION AL ANTIGENO Y POLIPEPTIDO QUE INCLUYE SECCION DE TRANSPORTE.

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

National Biblio. Data
Patent Family

Office

Mexico

Application Number 2019005756

Application Date 16.05.2019

Publication Number 2019005756

Publication Date 14.08.2019

Publication Kind A

IPC

CPC

View more classifications

View less classifications

Applicants CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventors Hiroyuki ISHIKAWA
Naoka HIRONIWA
Tomoyuki IGAWA

Priority Data 2016-229794 28.11.2016 JP

Title

(EN) DOMINIO DE UNION AL ANTIGENO Y POLIPEPTIDO QUE INCLUYE SECCION DE TRANSPORTE.

(ES) DOMINIO DE UNION AL ANTIGENO Y POLIPEPTIDO QUE INCLUYE SECCION DE TRANSPORTE.

Abstract

(EN) The present invention pertains to: a polypeptide that includes an antigen-binding domain and a conveying section having an inhibitory domain for inhibiting the antigen-binding activity of the antigen-binding domain, and that has a half-life longer than that of the antigen-binding domain when existing alone; a production method and screening method for the polypeptide; a pharmaceutical composition containing the polypeptide; a production method and screening method for a single-domain antibody the antigen-binding activity of which is inhibited by being associated with a specific VL/VH/VHH; and a library of fused polypeptides including a single-domain antibody the antigen-binding activity of which is inhibited by being associated with a specific VL/VH/VHH.

(ES) La presente invención se refiere a un polipéptido que comprende un dominio de unión al antígeno y una porción portadora que tiene un dominio de inhibición que inhibe la actividad de unión al antígeno del dominio de unión al antígeno, y que tiene una semivida más prolongada que aquella del dominio de unión al antígeno que existe solo, a métodos para producir y seleccionar el polipéptido, a una composición farmacéutica que comprende el polipéptido, a métodos para producir y seleccionar un anticuerpo de dominio único cuya actividad de unión al antígeno sea inhibida al asociarse con una VL, VH o VHH particular, y a una biblioteca del polipéptido de fusión que incluye un anticuerpo de dominio único cuya actividad de unión al antígeno sea inhibida al asociarse con una VL, VH o VHH particular.

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38	Medicinal preparations containing peptides
16	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology

C	CHEMISTRY; METALLURGY
40	COMBINATORIAL TECHNOLOGY
B	COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
30	Methods of screening libraries
04	by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. MX2019005756 - DOMINIO DE UNION AL ANTIGENO Y POLIPEPTIDO QUE INCLUYE SECCION DE TRANSPORTE.

G	PHYSICS
01	MEASURING; TESTING
N	INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33	Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48	Biological material, e.g. blood, urine
50	Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68	involving proteins, peptides or amino acids
6803	General methods of protein analysis not limited to specific proteins or families of proteins
6845	Methods of identifying protein-protein interactions in protein mixtures

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37	Drugs for immunological or allergic disorders
02	Immunomodulators
06	Immunosuppressants, e.g. drugs for graft rejection

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
16	Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
62	the modifying agent being a protein, peptide or polyamino acid
65	Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
62	the modifying agent being a protein, peptide or polyamino acid
64	Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
2319	Fusion polypeptide
33	fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
16	Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18	against material from animals or humans
28	against receptors, cell surface antigens or cell surface determinants